Swiss pharmaceutical giant Novartis believes the anti-malaria drug hydroxychloroquine offers one of the best hopes to combat coronavirus and has donated 130 million doses as part of the pandemic response.
This content was published on
3 minutes
swissinfo.ch/mga
Español
es
Medicamento antimalaria puede matar al coronavirus
“Pre-clinical studies in animals as well as the first data from clinical studies show that hydroxychloroquine kills the coronavirus,” Novartis Chief Executive Vas Narasimhan told the SonntagsZeitung newspaperExternal link on March 29.
On April 3, Novartis said it was donating a “considerable amount” of the drug to the Swiss authorities, which would organise distribution to hospitals. Switzerland is thus the first European country – and second country in the world after the US – to receive some doses.
Hydroxychloroquine, produced by Novartis’s Sandoz division among other companies, is also used to treat lupus and arthritis. “We are working with Swiss hospitals on possible treatment protocols for the clinical use of this drug [against Covid-19], but it is too early to say anything definitive,” added Narasimhan.
Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of Covid-19.
Novartis had previously issued a pledgeExternal link to give away 130 million doses of the drug, including 50 million 200 gram doses it already has stockpiled. It has been reported that the United States has accepted 30 million doses.
“Novartis will work with stakeholders including the World Health Organization to determine the best distribution of the medicine to ensure broad access to patients most in need of this medicine globally,” the company stated on March 20.
Working with the US
Other Novartis drugs are also being explored as possible treatment for Covid-19 including the multiple sclerosis drug Gilenya and the cancer drug Jakavi, Narasimhan told the paper.
The Swiss drugmaker said on March 20 it was working with the US Food and Drug Administration (FDA) and the US government to initiate a phase 3 trial to evaluate the safety of the drug used to treat cytokine release syndrome and rheumatoid arthritis, two inflammatory diseases.
Decree
On April 3 Switzerland sought to speed access to drugs that could be used against Covid-19 with an order that allows them to be deployed in hospitals before getting formal approval by the country’s regulator.
The decree covers generic malaria medicine hydroxychloroquine, Abbvie’s HIV drug Kaletra, Gilead Science’s experimental remdesivir and Roche’s Actemra, all of which are being studied for potential use against coronavirus.
Swissmedic, responsible for vetting drugs in the country, also will get new powers to approve deviations from some legal requirements for medicines under review, the government said.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Is your place of origin, your Heimatort, important to you?
Every Swiss citizen has a Heimatort, a place of origin, but many have never visited theirs. What’s your relationship with your Heimatort? What does it mean to you?
An atomic ‘tick-tock’ with Swiss technology heads to space to test the Einstein effect
This content was published on
On Monday, the European Space Agency (ESA) launched the ACES set of atomic clocks to measure the effect of gravity on the passage of time.
Swiss Guard swearing-in ceremony postponed following Pope Francis death
This content was published on
The swearing-in ceremony of the Pontifical Swiss Guard, which usually takes place on May 6 each year, has been postponed to a date to be announced next autumn.
Swiss medical device maker Ypsomed to sell diabetes business
This content was published on
Bern-based injection device manufacturer Ypsomed announced on Tuesday that it was selling its diabetes-related activities.
Award-winning Swiss author and scholar Peter von Matt dies aged 87
This content was published on
The Alemannic writer and former professor of German literature Peter von Matt died on Monday in Zurich at the age of 87, following a long illness.
Swiss foreign minister spoke with Iranian counterpart about US dialogue
This content was published on
Swiss Foreign Minister Ignazio Cassis has spoken with his Iranian counterpart Abbas Araghchi about the current dialogue between the US and Iran.
Swiss foreign minister appeals for cohesion and dialogue at Expo in Japan
This content was published on
Swiss Foreign Minister Ignazio Cassis called for cohesion and dialogue at the opening of the Swiss National Day at Expo 2025 in Osaka, Japan, on Tuesday.
Switzerland postpones launch of emergency number for domestic violence victims
This content was published on
The launch of the “142” emergency number, which aims to help victims of domestic violence in Switzerland, has been postponed to May 2026.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis steps up coronavirus fight as part of new collaboration
This content was published on
Several big pharmaceutical companies have joined forces with the Bill & Melinda Gates Foundation in response to the coronavirus pandemic.
Swiss doctors call for better supplies of vaccines
This content was published on
Carlos Quinto, a board member of the Swiss Medical AssociationExternal link (FMH), told the Swiss public broadcaster SRFExternal link that stocks of Pneumovax, which helps patients with respiratory diseases or immune deficiencies to ward off pneumonia, have run out. “Patients are calling us and we then have to tell them that there is nothing left,”…
Who decides who gets access to the silver bullet to Covid-19?
This content was published on
Our regular analysis of what the biggest global companies in Switzerland are up to. This week: multinationals confront national interests.
WHO and Roche launch trials of potential coronavirus treatments
This content was published on
Roche is launching a clinical trial of a potential new Covid-19 drug, adding to rapidly growing investments in combating coronavirus.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.